Impel raises $67.5M as it eyes filing for nasal migraine drug by Phil Taylor Thursday, December 6, 2018 Impel’s championing of nasal delivery of drugs has been rewarded with new financing that will help it advance three drugs through the clinic.
Milestone nets $80M for at-home trial of tachycardia nasal spray by Conor Hale Thursday, October 25, 2018 Milestone Pharmaceuticals has brought in $80 million to fund an at-home, phase 3 clinical trial of its nasal spray for bringing down high heart rates.
Lyra bags $29.5M to push chronic sinusitis drug into phase 2 by Amirah Al Idrus Wednesday, September 26, 2018 Lyra Therapeutics' series B will move its lead program, a rhinosinusitis treatment based on its transmucosal drug delivery platform, into phase 2.
Fresh from FDA approval, Optinose files for $100M IPO by Nick Paul Taylor Wednesday, September 20, 2017 Days after the FDA approved Optinose’s nasal polyp drug, its commercialization will be the focus of a post-IPO spending spree.
Medtronic wins expanded indication for sinus dilation balloon by Amirah Al Idrus Tuesday, July 12, 2016 The FDA expanded the indication for Medtronic’s NuVent sinus dilation balloon to include patients with scarred, granulated or previously surgically altered tissue.
